LINK-BioBAY TOKYO to Launch Activities in San Diego During BIO 2026

Expanding Japan’s Life Sciences Globally Through Startup Support and Podcast Participation

With the world’s largest life sciences event, BIO International Convention 2026, fast approaching this month, many are planning their visit to San Diego.
During the same period, LINK-J will roll out multiple initiatives under LINK-BioBAY TOKYO.
We encourage you to stay tuned as we accelerate the global expansion of Japan-originated life sciences.

1. Supporting a Startup Participating in BIO International

LINK-BioBAY TOKYO provides financial support for a participation pass for a startup expected to succeed in the global market at BIO International Convention 2026. On this occasion, we are pleased to support Senno Therapeutics, Inc.
If you are interested in connecting with this company, please contact them directly.

Startup

Company

Overview

Senno Therapeutics, Inc.

[Company Overview]
- Senno Therapeutics is a biotechnology company developing regenerative medicine therapies using iPS cell–derived hepatic progenitor cells.
- Through its proprietary cell differentiation and culture technologies, the company is able to reconstruct liver functions and create cell-based products with strong manufacturability.
- Senno Therapeutics aims to establish new treatment options for lethal liver diseases.

[BIO Partnering Goals & Needs]
- We are currently raising capital in our seed round and rapidly accelerating research and development toward entering clinical trials.
- Our top priority during BIO International is to meet investors who share our vision of creating a new therapeutic paradigm—an alternative to organ transplantation—in the fields of regenerative medicine, cell therapy, and liver diseases.
- In parallel, with an eye toward future clinical development and global expansion, we are also actively exploring strategic partnerships with pharmaceutical companies.

2. LINK-J to Appear on a BioLabs Podcast

LINK-J President & COO, Dr. Ikuo Hayashi, will appear on a podcast hosted by BioLabs.

This podcast series features interview-style discussions recorded at the BioLabs booth during BIO.
This year’s episode, “Episode 11: BioLabs Tokyo Spotlight,” will focus on the upcoming launch of BioLabs Tokyo.

Through initiatives such as the Tokyo Metropolitan Government project “TIB CATAPULT / LINK-BioBAY TOKYO,” jointly operated by LINK-J, BioLabs, and Mitsui Fudosan, as well as BioLabs Tokyo, BioLabs’ first directly operated coworking wet lab in Asia, efforts are being strengthened to support Japanese startups in their global expansion.

Theme:
Episode 11: BioLabs Tokyo Spotlight

Speakers:

[Guests]
Tomoyoshi Koyanagi, Ph.D.
(Program-Specific Professor, Director of Business Development Office, Institute for Advancement of Clinical and Translational Science (iACT), KYOTO UNIVERSITY HOSPITAL)

Ikuo Hayashi, Ph.D., MBA, R.Ph.
(President & COO, LINK-J / Executive Life Sicence Strategist, Life Science Innovation Department, Innovation Promoting Division, Mitsui Fudosan Co., Ltd)

[Moderator]
Johannes Fruehauf, PhD, MD（Founder & CEO, BioLabs）

Topic:
Tokyo has its own rhythm, scientific culture, and way of doing things.
In this episode, we will explore BioLabs Tokyo and discuss how a city renowned for precision and innovation is finding its place within the global biotech ecosystem - and what Japan’s biotech ambitions mean for the future of purpose-driven science worldwide.

Distribution:
To be released on BioLabs’ YouTube channel and LinkedIn.